

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-15. (Canceled)

16. (Previously Presented) A method for treating rheumatoid arthritis in a human subject, said method comprising administering to said subject a therapeutically effective amount of an IL-12 antagonist that binds with IL-12, wherein said antagonist is chosen from a group consisting of an antibody immunoreactive with IL-12 and an antibody fragment immunoreactive with IL-12.

17. (Canceled)

18. (Previously Presented) The method of claim 16, wherein said antagonist is administered in combination with a pharmaceutically acceptable carrier.

19. (Previously Presented) The method of claim 16, wherein said antagonist is an antibody immunoreactive with IL-12.

20. (Previously Presented) The method of claim 16, wherein said antagonist is an antibody fragment immunoreactive with IL-12.

21. (Previously Presented) The method of claim 16, wherein the antibody is a monoclonal antibody.

22. (Previously Presented) The method of claim 16, wherein the antibody binds to a heterodimer comprised of a 40 kD subunit and an 35 kD subunit of IL-12.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

23. (Canceled)

24. (Canceled)

7
25. (Previously Presented) The method of claim 16, wherein said antagonist is administered in a dose of from about 0.05 to about 25 mg/kg.

8
26. (Previously Presented) The method of claim 16, wherein said antagonist is administered in a dose of from about 0.2 to about 2 mg/kg.

9
27. (Previously Presented) The method of claim 16, wherein said antagonist is administered intravenously.

10
28. (Previously Presented) The method of claim 16, wherein said antagonist is administered subcutaneously.

11
29. (Previously Presented) The method of claim 16, wherein said antagonist is administered cutaneously.

12
30. (Previously Presented) The method of claim 16, wherein said antagonist is administered in combination with other therapies for autoimmune conditions.

13
31. (Previously Presented) The method of claim 30, wherein said therapies comprise steroidal or other anti-inflammatory therapies.

32-43. (Canceled)

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com